Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including T-cell therapies and bispecific antibodies. Here, our expert panel discuss BCMA and SLAMF7 targeting CAR T-cells, bispecific T-cell engaging antibodies, and recent clinical trials in these areas. From the Myeloma 2018 meeting in San Diego, CA, Andrzej Jakubowiak, MD, PhD, from the University of Chicago Medical Center, Chicago, IL chairs a discussion with James Kochenderfer, MD, of the National Cancer Institute, Bethesda, MD, and Adam Cohen, MD, of the University of Pennsylvania, Philadelphia, PA.
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
